Treatment of Paget's disease of bone with alendronate

Bone

Volumn 24, Issue 5 SUPPL., 1999, Pages 59S-61S

  Lombardi, A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; ETIDRONIC ACID; PLACEBO; PYRIDINOLINE; VITAMIN D;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOD REGURGITATION; HUMAN; HYDROXYPROLINE URINE LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; SCINTIGRAPHY;

EID: 0032904209     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00063-0     Document Type: Article

References (17)

1. De Groen P.C., et al. Esophagitis associated with the use of alendronate. New Engl J Med. 335:1996;1016-1021.
2. Delmas P.D., Meunier P.J. The management of Paget's disease of bone. New Engl J Med. 336:1997;5558-5566.
3. Dodd G.W., et al. Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD. Br J Radiol. 60:1987;849-860.
4. Doyle F.H., et al. Radiological evidence of a dose-related response to long-term treatment of Paget's disease with human calcitonin. Br J Radiol. 47:1974;1-8.
5. Ebetino F.H., et al. Mechanism of action of etidronate and other bisphosphonates. Rev Contemp Pharmacother. 9:1998;233-243.
6. Fleisch H. Bisphosphonates Mechanism of action . Endocrine Rev. 19:1998;80-100.
7. Hosking D., et al. Paget's disease of bone Diagnosis and management . Br Med J. 312:1996;491-494.
8. Lufkin E.G., et al. Pamidronate An unrecognized problem in gastrointestinal tolerability . Osteopor Int. 4:1994;320-322.
9. Murphy W., et al. Healing of lytic Paget bone disease with diphosphonate therapy. Radiology. 134:1980;635-637.
10. Patel S., et al. Determinants of remission of Paget's disease of bone. J Bone Miner Res. 12:1993;1467-1473.
11. Reid I.R., et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate A randomized, placebo-controlled trial . Am J Med. 171:1996;341-348.
12. Rodan G.A. Mechanism of action of bisphosphonates. Annu Rev Pharmacol Toxicol. 38:1998;375-388.
13. Rodan G.A., et al. Preclinical pharmacology of alendronate. Osteopor Int. 3:(Suppl. 3):1993;S7-S12.
14. Singer F.R., et al. Pharmacologic effects of salmon calcitonin. Talmage R.V., Munson P.L. Calcium, Parathyroid Hormone and the Calcitonins. 1972;89-96 Excerpta Medica, Amsterdam.
15. Siris E.S., et al. Clinical and biochemical effect of EHDP in Paget's disease of bone Patterns of response to initial treatment and to long-term therapy . Metab Bone Dis Rel Res. 5:1981;301-308.
16. Siris E.S., et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 81:1996;961-967.
17. Siris, E. S. et al. J Bone Miner Res 13:1032-1038; 1998.